The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)


Chemical Compound Review

Pyridinoline     (2S,5R)-2-amino-6-[4-[(2S)-2- amino-2...

Synonyms: HMDB00851, KST-1A7109, AC1L2XZB, AR-1A3536, AC1Q228H, ...
This record was replaced with 105069.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


Psychiatry related information on (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


High impact information on (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


Chemical compound and disease context of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


Biological context of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid

  • The increase in pyridinoline cross-links is likely to be the result of increased activity of the enzyme responsible for the hydroxylation of the telopeptides (telopeptide lysyl hydroxylase, or TLH) [17].
  • By analyzing the genetic defect of Bruck syndrome, which is characterized by a pyridinoline deficiency in bone collagen, we found two missense mutations in exon 17 of PLOD2, thereby identifying PLOD2 as a putative TLH gene [17].
  • After menopause, free deoxypyridinoline (free D-Pyr) excretion measured by HPLC without urine hydrolysis and expressed as a fraction of the total excretion was lower than in premenopausal women (45 +/- 15% vs. 59 +/- 12%, p < 0.005), whereas the fraction of free Pyr was not changed [18].
  • The Dpd antibody exhibited less than 1% cross-reaction with free pyridinoline and was shown to react only with free Dpd in urine, having no significant interaction with peptide forms of the crosslinks [19].
  • Predominantly type II collagen was present in the alginate bead, as reflected by the unique extent of lysyl hydroxylation, glycosylation, and pyridinoline crosslink formation measured [20].

Anatomical context of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


Associations of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid with other chemical compounds


Gene context of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


Analytical, diagnostic and therapeutic context of (2S,5R)-2-amino-6-[4-[(2S)-2-amino-2-carboxy-ethyl]-5-[(3S)-3-amino-3-carboxy-propyl]-3-hydroxy-1-pyridyl]-5-hydroxy-hexanoic acid


  1. The bone density of female twins discordant for tobacco use. Hopper, J.L., Seeman, E. N. Engl. J. Med. (1994) [Pubmed]
  2. Mechanism of collagen network stabilization in human irreversible granulomatous liver fibrosis. Ricard-Blum, S., Bresson-Hadni, S., Guerret, S., Grenard, P., Volle, P.J., Risteli, L., Grimaud, J.A., Vuitton, D.A. Gastroenterology (1996) [Pubmed]
  3. Changes in metabolism of collagen in genitourinary prolapse. Jackson, S.R., Avery, N.C., Tarlton, J.F., Eckford, S.D., Abrams, P., Bailey, A.J. Lancet (1996) [Pubmed]
  4. Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI. Steinmann, B., Eyre, D.R., Shao, P. Am. J. Hum. Genet. (1995) [Pubmed]
  5. Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis. Ricard-Blum, S., Bresson-Hadni, S., Vuitton, D.A., Ville, G., Grimaud, J.A. Hepatology (1992) [Pubmed]
  6. Bone mass and metabolism in women aged 45-55. Garton, M., Martin, J., New, S., Lee, S., Loveridge, N., Milne, J., Reid, D., Reid, I., Robins, S. Clin. Endocrinol. (Oxf) (1996) [Pubmed]
  7. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Paoletti, A.M., Pilloni, M., Orrù, M., Floris, S., Pistis, M., Guerriero, S., Ajossa, S., Melis, G.B. Maturitas. (2002) [Pubmed]
  8. Effects of rhIGF-I administration on bone turnover during short-term fasting. Grinspoon, S.K., Baum, H.B., Peterson, S., Klibanski, A. J. Clin. Invest. (1995) [Pubmed]
  9. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. Kimble, R.B., Vannice, J.L., Bloedow, D.C., Thompson, R.C., Hopfer, W., Kung, V.T., Brownfield, C., Pacifici, R. J. Clin. Invest. (1994) [Pubmed]
  10. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Cosman, F., Shen, V., Xie, F., Seibel, M., Ratcliffe, A., Lindsay, R. Ann. Intern. Med. (1993) [Pubmed]
  11. Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts. Pischon, N., Darbois, L.M., Palamakumbura, A.H., Kessler, E., Trackman, P.C. J. Biol. Chem. (2004) [Pubmed]
  12. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy. Cosman, F., Nieves, J., Shen, V., Lindsay, R. J. Bone Miner. Res. (1995) [Pubmed]
  13. The short term effects of tamoxifen on bone turnover in older women. Kenny, A.M., Prestwood, K.M., Pilbeam, C.C., Raisz, L.G. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  14. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. Bettica, P., Taylor, A.K., Talbot, J., Moro, L., Talamini, R., Baylink, D.J. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  15. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Hernández, E., Valera, R., Alonzo, E., Bajares-Lilue, M., Carlini, R., Capriles, F., Martinis, R., Bellorin-Font, E., Weisinger, J.R. Kidney Int. (2003) [Pubmed]
  16. Bone and collagen markers in preterm infants: relationship with growth and bone mineral content over the first 10 weeks of life. Crofton, P.M., Shrivastava, A., Wade, J.C., Stephen, R., Kelnar, C.J., Lyon, A.J., McIntosh, N. Pediatr. Res. (1999) [Pubmed]
  17. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. van der Slot, A.J., Zuurmond, A.M., Bardoel, A.F., Wijmenga, C., Pruijs, H.E., Sillence, D.O., Brinckmann, J., Abraham, D.J., Black, C.M., Verzijl, N., DeGroot, J., Hanemaaijer, R., TeKoppele, J.M., Huizinga, T.W., Bank, R.A. J. Biol. Chem. (2003) [Pubmed]
  18. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Garnero, P., Gineyts, E., Arbault, P., Christiansen, C., Delmas, P.D. J. Bone Miner. Res. (1995) [Pubmed]
  19. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. Robins, S.P., Woitge, H., Hesley, R., Ju, J., Seyedin, S., Seibel, M.J. J. Bone Miner. Res. (1994) [Pubmed]
  20. Synthesis of collagen by bovine chondrocytes cultured in alginate; posttranslational modifications and cell-matrix interaction. Beekman, B., Verzijl, N., Bank, R.A., von der Mark, K., TeKoppele, J.M. Exp. Cell Res. (1997) [Pubmed]
  21. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Takahashi, M., Kushida, K., Ohishi, T., Kawana, K., Hoshino, H., Uchiyama, A., Inoue, T. Arthritis Rheum. (1994) [Pubmed]
  22. Blockade of parathyroid hormone-related protein prevents joint destruction and granuloma formation in streptococcal cell wall-induced arthritis. Funk, J.L., Chen, J., Downey, K.J., Davee, S.M., Stafford, G. Arthritis Rheum. (2003) [Pubmed]
  23. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Miossec, P., Chomarat, P., Dechanet, J., Moreau, J.F., Roux, J.P., Delmas, P., Banchereau, J. Arthritis Rheum. (1994) [Pubmed]
  24. The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. St Clair, E.W., Wilkinson, W.E., Pisetsky, D.S., Sexton, D.J., Drew, R., Kraus, V.B., Greenwald, R.A. Arthritis Rheum. (2001) [Pubmed]
  25. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. Hanson, D.A., Eyre, D.R. J. Biol. Chem. (1996) [Pubmed]
  26. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion. Shen, V., Birchman, R., Wu, D.D., Lindsay, R. J. Bone Miner. Res. (2000) [Pubmed]
  27. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. Guañabens, N., Parés, A., Alvarez, L., Martínez de Osaba, M.J., Monegal, A., Peris, P., Ballesta, A.M., Rodés, J. J. Bone Miner. Res. (1998) [Pubmed]
  28. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. Bonde, M., Qvist, P., Fledelius, C., Riis, B.J., Christiansen, C. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  29. Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. Robins, S.P. Biochem. J. (1983) [Pubmed]
  30. Can biochemical markers predict bone loss at the hip and spine?: a 4-year prospective study of 141 early postmenopausal women. Keen, R.W., Nguyen, T., Sobnack, R., Perry, L.A., Thompson, P.W., Spector, T.D. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1996) [Pubmed]
  31. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Manicourt, D.H., Poilvache, P., Van Egeren, A., Devogelaer, J.P., Lenz, M.E., Thonar, E.J. Arthritis Rheum. (2000) [Pubmed]
  32. Association between AAAG repeat polymorphism in the P3 promoter of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene and adult height, urinary pyridinoline excretion, and promoter activity. Minagawa, M., Yasuda, T., Watanabe, T., Minamitani, K., Takahashi, Y., Goltzman, D., White, J.H., Hendy, G.N., Kohno, Y. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  33. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Kimble, R.B., Matayoshi, A.B., Vannice, J.L., Kung, V.T., Williams, C., Pacifici, R. Endocrinology (1995) [Pubmed]
  34. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. van der Slot, A.J., Zuurmond, A.M., van den Bogaerdt, A.J., Ulrich, M.M., Middelkoop, E., Boers, W., Karel Ronday, H., DeGroot, J., Huizinga, T.W., Bank, R.A. Matrix Biol. (2004) [Pubmed]
  35. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Erlichman, C., Adjei, A.A., Alberts, S.R., Sloan, J.A., Goldberg, R.M., Pitot, H.C., Rubin, J., Atherton, P.J., Klee, G.G., Humphrey, R. Ann. Oncol. (2001) [Pubmed]
  36. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Hoskin, P.J., Stratford, M.R., Folkes, L.K., Regan, J., Yarnold, J.R. Lancet (2000) [Pubmed]
  37. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Pecherstorfer, M., Seibel, M.J., Woitge, H.W., Horn, E., Schuster, J., Neuda, J., Sagaster, P., Köhn, H., Bayer, P., Thiébaud, D., Ludwig, H. Blood (1997) [Pubmed]
  38. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. Seibel, M.J., Woitge, H., Scheidt-Nave, C., Leidig-Bruckner, G., Duncan, A., Nicol, P., Ziegler, R., Robins, S.P. J. Bone Miner. Res. (1994) [Pubmed]
  39. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. Delmas, P.D., Gineyts, E., Bertholin, A., Garnero, P., Marchand, F. J. Bone Miner. Res. (1993) [Pubmed]
WikiGenes - Universities